Gordon Gary B. 4
4 · TriSalus Life Sciences, Inc. · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
TriSalus (TLSI) Director Gary B. Gordon Buys 9,756 Shares
What Happened
Gary B. Gordon, a director of TriSalus Life Sciences, purchased 9,756 shares in an open-market transaction on February 23, 2026 at $4.10 per share, for a total cost of $40,000. This was a straight purchase (transaction code P), not an option exercise or award.
Key Details
- Transaction date and price: Feb 23, 2026 — 9,756 shares at $4.10 each.
- Total value: $40,000.
- Transaction type: Open-market purchase (Form 4 code P).
- Shares owned after transaction: Not specified in the provided filing.
- Footnotes/plans: No 10b5-1 plan, tax-withholding, or other footnotes were indicated in the summary provided.
- Filing timeliness: Report filed on Feb 23, 2026 (same date as the transaction) — appears timely.
Context
This was a simple open-market buy by a company director. Purchases by insiders can be taken as one data point about insider sentiment, but they should be weighed together with other insider activity, company fundamentals, and public disclosures. This filing does not indicate an exercise, gift, or sale — just a straightforward purchase.
Insider Transaction Report
Form 4
Gordon Gary B.
Director
Transactions
- Purchase
Common Stock
2026-02-23$4.10/sh+9,756$40,000→ 9,756 total
Signature
/s/ Mary Szela, Attorney-in-Fact|2026-02-23